...

首页> 外文期刊>Journal of Clinical Oncology >Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase II Study of the Efficacy and Safety of Apricoxib in Combination With Either Docetaxel or Pemetrexed in Patients With Biomarker-Selected Non-Small-Cell Lung Cancer

【24h】

Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase II Study of the Efficacy and Safety of Apricoxib in Combination With Either Docetaxel or Pemetrexed in Patients With Biomarker-Selected Non-Small-Cell Lung Cancer

机译：生物标志物选择的非小细胞肺癌患者中阿波昔布联合多西他赛或培美曲塞的疗效和安全性的随机，双盲，安慰剂对照多中心II期研究

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Purpose

机译：目的

著录项

来源
《Journal of Clinical Oncology》 |2015年第2期|共8页
作者
Edelman Martin J.; Tan Ming T.; Fidler Mary J.; Sanborn Rachel E.; Otterson Greg; Sequist Lecia V.; Evans Tracey L.; Schneider Bryan J.; Keresztes Roger; Rogers John S.; de Mayolo Jorge Antunez; Feliciano Josephine; Yang Yang; Medeiros Michelle; Zaknoen Sara L.;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类
关键词

相似文献

外文文献
中文文献
专利

1. Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase II Study of the Efficacy and Safety of Apricoxib in Combination With Either Docetaxel or Pemetrexed in Patients With Biomarker-Selected Non-Small-Cell Lung Cancer [J] . Edelman Martin J., Tan Ming T., Fidler Mary J., Journal of Clinical Oncology . 2015,第2期

机译：生物标志物选择的非小细胞肺癌患者中阿波昔布联合多西他赛或培美曲塞的疗效和安全性的随机，双盲，安慰剂对照多中心II期研究
2. A randomized, placebo-controlled, multicenter, biomarker-selected, phase 2 study of apricoxib in combination with erlotinib in patients with advanced non-small-cell lung cancer. [J] . Barbara J Gitlitz, Eric Bernstein, Edgardo S Santos, Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer . 2014,第4期

机译：一种随机，安慰剂控制，多中心，生物标志物 - 选择2阶段2研究杏子患者在晚期非小细胞肺癌患者中与厄洛替尼相结合。
3. A randomized, placebo-controlled, multicenter, biomarker-selected, phase 2 study of apricoxib in combination with erlotinib in patients with advanced non-small-cell lung cancer. [J] . Barbara J Gitlitz, Eric Bernstein, Edgardo S Santos, Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer . 2014,第4期

机译：阿普昔布联合厄洛替尼治疗晚期非小细胞肺癌的随机，安慰剂对照，多中心，生物标志物选择的2期研究。
4. Pemetrexed versus docetaxel single agent chemotherapy in chemotherapy-naive elderly patients with advanced non-small cell lung cancer [C] . Hua Xin, Zhenguo Han, Haibo Huang 2011 International Conference on Human Health and Biomedical Engineering . 2011

机译：培美曲塞与多西他赛单药化疗在未接受化疗的老年晚期非小细胞肺癌患者中的作用
5. A Phase II, Randomized, Double-Blind, Placebo-Controlled Trial of Fish Oil (Eicosapentaenoic Acid and Docosahexaenoic Acid) on Lung and Systemic Inflammation in Patients with Acute Lung Injury. [D] . Stapleton, Renee Doney. 2010

机译：鱼油（二十碳五烯酸和二十二碳六烯酸）对急性肺损伤患者的肺和全身炎症的II期，随机，双盲，安慰剂对照试验。
6. Randomized Double-Blind Placebo-Controlled Multicenter Phase II Study of the Efficacy and Safety of Apricoxib in Combination With Either Docetaxel or Pemetrexed in Patients With Biomarker-Selected Non–Small-Cell Lung Cancer [O] . Martin J. Edelman, Ming T. Tan, Mary J. Fidler, -1

机译：生物标志物选择的非小细胞肺癌患者中阿波昔布联合多西他赛或培美曲塞的疗效和安全性的随机双盲安慰剂对照多中心II期研究
7. Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase II Study of the Efficacy and Safety of Apricoxib in Combination With Either Docetaxel or Pemetrexed in Patients With Biomarker-Selected Non–Small-Cell Lung Cancer [O] . Martin J. Edelman, Ming T. Tan, Mary J. Fidler, 2015

机译：随机，双盲，安慰剂控制，多中心期II研究Apricoxib的疗效和安全性与生物标志物选择的非小细胞肺癌患者的多西紫杉醇或培养基

获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

客服微信
服务号